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Wnt and Hedgehog signaling pathways play central roles in embryogenesis, stem cell maintenance, 
and tumorigenesis. However, mechanisms by which these two pathways interact are not well-
understood. Here, we identified a novel mechanism by which Wnt signaling pathway stimulates the 
transcriptional output of Hedgehog signaling. Wnt/β-catenin signaling induces expression of an 
RNA-binding protein, CRD-BP, which, in turn, binds and stabilizes GLI1 mRNA, causing an 
elevation of GLI1 expression and transcriptional activity. The newly described mode of regulation 
of GLI1 appears to be important to several functions of Wnt, including survival and proliferation of 






Wnt and Hedgehog (Hh) are two major pathways that are critical in embryonic development, stem 
cell maintenance, and tumorigenesis. Both signaling pathways play critical roles in patterning, 
morphogenesis and proliferation during embryogenesis, and in tumorigenesis.  
β-catenin is a pivotal player in the canonical signaling pathway initiated by Wnt proteins. This 
pathway has been shown to control the establishment of the body axis at the very early stages of 
embryogenesis and the development of many organs and tissues, including brain, limbs, kidney, 
reproductive tract, teeth and mammary glands (reviewed in (1)). In the absence of Wnt signaling, β-
catenin (contained within a multiprotein complex of axin, APC and GSK3β) is phosphorylated by 
GSK3β and subsequently degraded by ubiquitin-dependent proteolysis. Following the binding of 
Wnt proteins to receptors of the Frizzled and LRP families on the cell surface, GSK3β is inactivated 
and unphosphorylated β-catenin is released from the complex. It is subsequently translocated into 
the nucleus, where it forms a complex with Tcf/Lef resulting in the activation of Wnt target genes. 
Mutational loss of APC, stabilizing mutations of β-catenin, or mutations in axin cause constitutive 
activation of the Wnt signaling pathway and lead to colorectal cancers (reviewed in (2)).  
 
The Hh signaling pathway is also crucial for growth, patterning, and morphogenesis of many 
organs. This pathway is mediated by the Ci/GLI family of zinc finger transcription factors. In the 
absence of the Hh ligand, its transmembrane receptor Patched (Ptch) inhibits the activity of another 
transmembrane protein, Smoothened (Smo), resulting in inactivation of Hh signaling. Binding of 
the Hh ligand to Ptch abrogates the inhibitory effect of Ptch on Smo, thereby activating the 
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transcription factor Ci/GLI. In vertebrates, three GLI genes have been identified, with GLI1 being 
predominantly a transcriptional activator and GLI2 and GLI3, acting as both activators and 
repressors. Aberrant regulation of the Hh pathway contributes to the development of many human 
cancers. Activating mutations of Smo or suppressing mutations of Ptch have been shown to 
constitutively activate the Hh signaling pathway (reviewed in (3)).  
 
The Wnt and Hh signaling pathways, being fundamental in the coordination of developmental 
transitions, have been postulated to interact, or cross-regulate at multiple levels, yet the mechanisms 
of these interactions are not clear. Some studies have suggested an antagonistic role of Hh signaling 
towards Wnt signaling. This antagonism has been reported during patterning of the dorsal somite in 
chick (4), in the mouse somitic mesoderm, possibly through up-regulation of SFRP2 (5), and in 
colonic epithelial cell differentiation and colorectal cancers, probably via a GLI1-mediated 
mechanism (6, 7). Conversely, a Gli-dependent activation of Wnt signaling has been demonstrated 
during ventro-posterior morphogenesis in Xenopus embryos (8) and during epithelial 
transformation, likely via Snail activation and E-cadherin inhibition (9). Active canonical Wnt 
signaling pathway has also been shown to be required for Hh pathway-driven development of basal 
cell carcinomas (10). Several reports have suggested that Hh signaling is controlled by Wnt 
signaling during embryogenesis (11, 12), and in development of colorectal cancers (13-15).  
 
The mechanisms of cross-regulation between Wnt and Hh signaling pathways are not well 
understood. In this study, we identify a novel mechanism by which Wnt signaling regulates the 
transcriptional outcome of Hh signaling pathway. We demonstrate that this mechanism employs 
GLI1 mRNA stabilization by the RNA-binding protein, CRD-BP, a direct target of the Wnt 
signaling pathway and show its importance for colorectal tumorigenesis. 
 5
Materials and Methods 
Expression vectors.  
The full-length GLI1 sub-cloned into pOTB7 (ATCC) was amplified by PCR using Pfu Turbo DNA 
polymerase (Stratagene) and cloned into two vectors: pTRE-Tight (Clontech) under the control of 
TRE promoter, and pcDNA3.1 (Invitrogen) downstream of the T7 promoter.  
The expression vectors for Flag-CRD-BP were a kind gift of Dr. J. Ross. CRD-BP shRNA was 
described previously (16). In brief, we used the siRNA Target Finder and Design Tool 
(http://www.ambion.com/techlib/misc/siRNA_finder.html) to select siRNA sequences. The 
annealed shRNA inserts were cloned into the pSinlencer 1.0-U6 siRNA expression vector in 
accordance with the recommendations of Ambion.  β-cateninS33Y and pHR-hTcf4 (wild type) were a 
gift from Drs. K. Kinzler and B. Vogelstein. GLI1 shRNAs were  kindly provided by Dr. F. 
Aberger, and 8X3’Gli BS-LucII (eight directly repeated copies of 3’Gli binding site from HNF3β 
floor plate enhancer cloned into pδ51LucII) was a gift of Dr. H. Sasaki. Plasmids for expression of 
β-galactosidase (pSV-40 β-galactosidase) were purchased from Promega (Madison, WI). 
Tissue culture and transfections.  
293T cells were obtained from ATCC, they were maintained in DMEM medium with 10% FBS and 
transfected with the calcium phosphate method (16). The cell lines HeLa, NIH3T3, HCT116, 
DLD1, HT-29, RKO, SW48, SW480, SW620 and CCD-841/CoTr were also obtained from ATCC 
and maintained in accordance with the ATCC’s recommendations. The cancer cell lines 
DLD1D7Δ15 and LS174 T-L8 were gifts from Dr. H. Clevers. These cell lines are characterized by 
constitutive activation of the β-catenin/Tcf signaling. DLD1D7Δ15 cells carry a mutation in APC 
while LS174 T-L8 cells have their mutation in β-catenin. Additionally, these cells carry a 
doxycycline-inducible dnTcf4 (17). They were maintained in RPMI medium with 5% FBS. All our 
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tissues culture media contained 1% penicillin and streptomycin. NIH 3T3, DLD1D7Δ15 and LS174 
T-L8 cells were transfected with Lipofectamine 2000 (Invitrogen) in accordance with the 
manufacturer’s recommendations. The amount of DNA in each transfection was kept constant by 
the addition of an appropriate amount of empty expression vector.  
The chlorobenzothiophene-containing Hh pathway agonist (SAG) obtained from Alexis 
Biochemicals was diluted in DMSO and used to treat DLD1D7 Δ 15 cells at the concentration of 
3nM for 30 hrs (18). Cyclopamine (Biomol) was diluted in DMSO as well and used at the 
concentration of 10μM (19) to treat DLD1D7 Δ15 cells for 24 hrs. 
Antibodies and immunotechniques. 
Antibodies against GLI1, β-actin (Santa Cruz Biotechnology) and Flag (Sigma-Aldrich) were 
purchased, as well as the secondary antibody conjugated with horseradish peroxidase (Chemicon). 
Antibody against CRD-BP was generous gift of Dr. J. Ross (20). Immunoblotting procedures were 
performed as described previously (21).  
Whole cell extracts.  
To obtain whole cell lysate for western blot analysis, the cells were lysed using a denaturing RIPA 
buffer containing PBS (pH 7.4), 0.5% sodium deoxycholate, 0.1% SDS, 1% (v/v) IGEPAL, 100 
mM sodium orthovanadate, and proteinase inhibitors cocktail (sigma).  
For UV-crosslinking reactions, protein extracts were made in non-denaturing lysis buffer containing 
10 mM HEPES (pH 7.6), 3 mM MgCl2, 40 mM KCl, 2 mM DTT, 5% (v/v) glycerol, 0.5% (v/v) 
IGEPAL, and proteinase inhibitors cocktail (Sigma). 
 
GLI1 mRNA degradation in vivo.  
293T cells were transfected by calcium phosphate method with 5 μg of Tet-off plasmid (Clontech), 
3 μg of pTRE-GLI1 and β-cateninS33Y/Tcf4 expression vectors (3 μg each) or 4 μg of FLAG-CRD-
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BP per 100-mm plate. At 48 h after transfection, the cells were treated with doxycycline (1 μg/ml) 
and harvested at different time points after treatment. The levels of GLI1 mRNA were analyzed by 
Northern blot analysis with a GLI1-specific probe.  
Luciferase Reporter Assays.  
NIH 3T3 cells, DLD1D7Δ15 cells and 293T cells were transfected by lipofection with 8X3’GLI 
BS-LucII reporter plasmid, pSV-40 β-galactosidase (Promega) and different additional plasmids as 
indicated in the Figures. Luciferase activity was estimated 48 hrs after transfection using luciferase 
reporter assay reagent (Promega). β-galactosidase used for normalization was estimated by the β-
galactosidase assay reagent (Pierce). 
in vitro transcription of labeled RNA with α-32P.  
The fragments encompassing nucleotides 41-990, 973-1824, 1808-2730 and 2713-3600 of GLI1 
cDNA were amplified by PCR downstream of the SP6 promoter using Pfu Turbo DNA polymerase 
(Stratagene). Primer sequences for PCR amplification are in the supplemental table 1. The full-
length GLI1 in the pOTB7 vector was linearized immediately 3' to the target DNA insert, and in 
vitro transcription was performed for the full length as well as for the fragments using SP6 DNA 
directed RNA polymerase to produce 5'-capped, uniformly labeled mRNAs according to the kit 
RiboprobeR in vitro Transcription Systems (Promega). Radiolabeled probes were prepared using [α-
32P] UTP (800 Ci/mmol) (Amersham). Following transcription, RNase-free DNase (Promega) was 
added to the mixture to remove the template DNA and the probe was precipitated with 0.5 volume 
of 7.5 M ammonium acetate in 2.5 volumes of ethanol, and resuspended in RNase-free water.  
UV cross-linking.  
20 μg of protein from the whole cell extract of 293T cells transfected with either Flag-CRD-BP 
expression vector or pcDNA3.1 plasmid were incubated with 1.5 x 106 cpm of each RNA probe in 
96-well plate at room temperature for 20 min in 20 μl of binding buffer (10 mM HEPES [pH 7.6], 3 
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mM MgCl2, 40 mM KCl, 2 mM DTT, 5% (v/v) glycerol, 0.5% (v/v) IGEPAL). Heparin and yeast 
tRNA were added to final concentrations of 2.5 μg/μl and 50 ng/μl respectively for an additional 10 
min. The 96-well plate was then placed on ice and irradiated at 254 nm UV light in a Stratalinker 
(Stratagen) for 30 min at a distance of 5 cm from the light source. RNA not associated with protein 
was digested with 100 U of RNase T1 (Ambion) for 20 min at room temperature and further 
digested with 25 μg of RNase A (SigmaAldrich) at 37oC for 15 min. The remaining RNA-protein 
complexes were incubated overnight with 2 μg of anti-Flag antibody and 25 μl of protein A/G-plus 
agarose beads (Santa Cruz). Immunoprecipitates were washed six times in lysis buffer, boiled with 
20 μl of sample buffer, and separated in 8% SDS-PAGE. The gel was dried and exposed to X-ray 
film for a week. 
Real time PCR. 
Real Time PCR for quantitative measurements in zebrafish embryos, in primary human tissue 
samples (16), in mouse tissue samples and in cell lines was done using SYBR Green PCR Core 
reagents (Applied Biosystems). Primer sequences for Gli1, Gli2, Gli3, Axin2, Tcf1 (22), Cyclin D1 
(23), c-myc (24), and CRD-BP are in the supplemental table 2. α-tubulin was used as a reference 
gene for zebrafish (25) and GAPDH as reference gene for human (16) and mouse samples. 
Zebrafish strains and embryo culture 
Adult zebrafish were maintained according to established methods (26). Embryos were obtained 
from natural matings and staged according to Kimmel et al. (27). Heterozygous Tg(hs:Gfp tcf) 
embryos (28) at shield stage (6 hpf) were heat shocked at 37°C for 30 or 45 minutes, then incubated 
at 29°C until they reached tailbud stage (10 hpf). Embryos expressing Gfp Tcf were identified by 





Results and Discussion 
 
Wnt/β-catenin signaling induces expression of GLI1. 
In order to analyze the effect of Wnt/β-catenin signaling on the modulation of the Hh pathway, we 
studied the expression of the GLI family transcription factors in different cell types after Wnt/β-
catenin signaling was either activated or inhibited. We observed an up-regulation of GLI1 mRNA 
levels in HeLa cells treated with recombinant Wnt3A protein (Figure 1a). Transfection of 293T 
cells with β-catenin and Tcf4 resulted in elevated expression of GLI1 mRNA and protein (Figure 
1b). Colorectal cancer cells DLD1D7Δ15 and LS174 T-L8, characterized by constitutive activation 
of the β-catenin/Tcf4 signaling, carry doxycycline-inducible dominant negative Tcf4 mutant 
(dnTcf4). Both of these cell lines showed a significant reduction in GLI1 expression in the presence 
of doxycycline at the RNA and protein levels (Figure 1c). Similarly, blocking canonical Wnt 
signaling with dnTCF in zebrafish embryos resulted in reduction of gli1 mRNA levels (Figure 1d). 
These results show that Wnt/β-catenin signaling induces GLI1 expression to the extent similar to 
other Wnt regulated genes (axin2 and Tcf1; Figure S1a-c) and this induction is evolutionary 
conserved and not cell type-restricted. Our findings corroborate a recent study that suggested 
enhancement of GLI transcriptional activity by β-catenin in different human cancer cells (14). Our 
results also show that GLI1 induction is Tcf-dependent, as over-expression of the dominant 






CRD-BP binds to the coding region of GLI1 mRNA and stabilizes it. 
In order to investigate the mechanism of GLI1 regulation by Wnt/β-catenin signaling, 293T cells 
transfected with β-catenin/Tcf were treated with actinomycin D to inhibit transcription, and GLI1 
mRNA expression was determined. In contrast to the regulation of Wnt transcriptional target, axin2 
(29-31), this treatment did not prevent β-catenin/Tcf-dependent GLI1 induction in 293T cells 
(Figures S2a-b), suggesting that up-regulation of GLI1 is post-transcriptional. Further studies using 
doxycycline-regulated expression of GLI1 showed that Wnt signaling stabilizes GLI1 mRNA in 
cells (Figure 2a). We have previously reported that Wnt/β-catenin signaling induces the expression 
of mRNA binding protein, CRD-BP (16). This protein was shown to bind and stabilize different 
mRNAs, including the mRNA of the proto-oncogene c-myc (32), the mRNA of the β-TrCP1 
ubiquitin ligase receptor (16, 33), and the mRNA of MDR1, the multidrug resistance P-glycoprotein 
gene (34). We sought to determine whether GLI1 mRNA expression could be affected by CRD-BP 
as well. We found that GLI1 mRNA half life was drastically increased when CRD-BP was over-
expressed (Figure 2a). Over-expression of CRD-BP also up-regulated steady state levels of GLI1 
mRNA and protein (Figure 2b). Because CRD-BP is an mRNA binding protein, we hypothesized 
that it might directly bind to GLI1 mRNA and induce its stabilization. Indeed, CRD-BP interacted 
directly with mRNA of GLI1 with the strongest binding observed within the first ~900 bases (41-
990) of the coding region of GLI1 mRNA (Figure 2c). Overall, these results suggest that, upon 
Wnt/β-catenin signaling activation, CRD-BP is up-regulated, binds to the GLI1 mRNA and 
stabilizes it. CRD-BP did not target GLI2 and GLI3 mRNAs. These data are anticipated, since β-
catenin/Tcf4 that up-regulates CRD-BP expression (16) could not induce GLI2 and GLI3 mRNA 
expression (Figure S2c).  
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Wnt/β-catenin signaling induces the expression and transcriptional activity of GLI1 in a CRD-
BP dependent manner. 
CRD-BP knock-down largely prevented β-catenin/Tcf-dependent GLI1 up-regulation in 293T cells, 
as well as in NIH3T3 cells (Figure 2d). Moreover, down-regulation of CRD-BP by shRNA 
prevented the induction of Gli1 transcriptional activity by the Wnt/β-catenin signaling (Figure 3a). 
Doxycyclin-induced inhibition of β-catenin/Tcf4 signaling resulted in down-regulation of GLI1-
dependent transcription, whereas CRD-BP was able to up-regulate GLI1-dependent transcriptional 
activity in DLD1D7Δ15 colorectal cancer cells, regardless of the status of Wnt/β-catenin signaling 
(Figure 3b). Knockdown of GLI1 abrogated CRD-BP-controlled regulation of GLI-dependent 
transcription (Figure 3c), confirming the specificity of CRD-BP’s role in GLI1 regulation. These 
results demonstrate that control of GLI1 expression and activity by the Wnt/β-catenin signaling 
depends on CRD-BP.  
 
Interestingly, this regulation of GLI-dependent transcriptional activity appears to be independent of 
upstream Hh signaling, as neither inhibitor (cyclopamine) nor activator (SAG) of SMO had any 
effect on either basal or Wnt- and CRD-BP-regulated GLI-luciferase (Figure 3b). These data, 
whereas confirming a previous observation that upstream Hh pathway inhibitors do not affect GLI 
transcriptional activity in colorectal cancer cells (19), suggest a novel, SMO-independent, mode of 
regulation of GLI transcriptional outcome by Wnt signaling pathway.  
 
GLI1 contributes to β-catenin and CRD-BP-dependent proliferation of colorectal cancer cells. 
Several reports point to the involvement of Hh signaling in the genesis of colorectal cancers (13, 
15), where the role of Wnt signaling is well established. Enhancement of GLI-transcriptional 
activity by β-catenin has been shown in different human cancer cells (14), although the mechanism 
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of this activation is not clear. Interestingly, a recent study reported the absence of canonical Hh 
signaling in a variety of epithelial (including colorectal) cancer cells (19). However, GLI1 protein 
was also found to be over-expressed in some colorectal cancers independently of Shh signaling (35, 
36). Taken together, these studies imply that Wnt signaling controls Hh signaling in colorectal 
cancers. In cancer cells, Hh is primarily a proliferative stimulus (37), and GLI1 is a transcriptional 
mediator of Hh signaling (38). Since GLI1 is also up-regulated by the Wnt/β-catenin signaling, we 
sought to investigate whether GLI1 contributes to Wnt/β-catenin-dependent proliferation of human 
colorectal cancer cells. To assess this function of Wnt/β-catenin-mediated up-regulation of GLI1, 
we tested whether GLI1 co-expression could rescue Wnt/β-catenin-dependent colony formation 
when this pathway is inhibited. GLI1 could indeed partially rescue the ability of DLD1D7Δ15 and 
LS174 T-L8 cells to form colonies when Wnt/β-catenin signaling was inhibited by doxycycline 
treatment-induced expression of dnTcf4 (Figure 4a). Interestingly, ectopic expression of GLI1 
failed to induce cyclin D1 and c-myc mRNA expression in the absence of Wnt signaling (Figure 
S4a), suggesting that the partial rescue of the ability of DLD1D7Δ15 and LS174 T-L8 cells to form 
colonies by GLI1 is probably independent of cyclinD1 and c-myc. In addition, although the knock 
down of CRD-BP may affect the proliferation of colorectal cancer cells via multiple mechanisms, 
our data showed that over-expression of GLI1 resulted in attenuation of the inhibitory effect of 
CRD-BP shRNA in colony formation in colorectal cancer cells DLD1D7Δ15 and LS174 T-L8 
(Figure 4b). This indicates that GLI1 contributes to Wnt- and CRD-BP-dependent proliferation of 
DLD1D7Δ15 and LS174 T-L8 cells. GLI1 did not affect the expression of cyclin D1 and c-myc 
mRNA in these experiments either (Figure S4b), also suggesting that other target genes are involved 
in partial rescue of these cell to form colonies by GLI1. GLI1 contribution to the growth of 
colorectal cancer cells was not limited to DLD1D7Δ15 and LS174 T-L8 cells: knockdown of GLI1 
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(using two independent GLI1-targeting shRNA constructs) drastically decreased the ability of 
SW480, SW620, and HCT116 cells to form colonies (Figure S5a-b) indicating a requirement for 
GLI1 in proliferation and survival of colorectal cancer cells. Our data support previous findings that 
showed the involvement of GLI1 in colorectal cancer cell proliferation (13, 15). In contrast, another 
study showed that GLI1 over-expression suppressed proliferation of SW480 and HCT116 colorectal 
cancer cells with activated Wnt signaling (7). These cells exhibit high levels of endogenous GLI1 
(Figure S5c), and, perhaps, over-expression of GLI1 does not represent relevant pathophysiological 
conditions. On the other hand, knockdown of GLI1 expression in a variety of colorectal cancer 
cells, including SW480 and HCT116, resulted in dramatic inhibition of colony formation (Figure 
S5a), further supporting the importance of GLI1 for the proliferation of colorectal cancer cells.  
 
Wnt/β-catenin pathway is an important player in colorectal carcinogenesis. We next assessed the 
expression of GLI1 in primary human colorectal tumor samples and colorectal cancer cell lines. We 
found that all human colorectal tumor samples previously characterized by an activation of β-
catenin and high levels of CRD-BP (16, 39) over-expressed GLI1 mRNA to different extents 
(Figure 4c). Similarly, we have found a positive correlation between activation of β-catenin 
signaling and expression of CRD-BP and GLI1 in a panel of established colorectal cancer cell lines 
(Figure S5c). We also analyzed ApcMin+/- mice, heterozygous for a nonsense mutation in the APC 
locus that predisposes them to the development of multiple adenomas throughout the entire 
intestinal tract (40), for expression of Gli1. These mice over-expressed Gli1 in their intestinal 
tumors but not in the normal intestine (Figures 4d and S6). These findings further support both a 
role for GLI1 in colorectal cancer formation and its regulation by Wnt/β-catenin signaling. 
Increased expression of GLI1 mRNA was previously reported in human colonic adenocarcinomas 
(13); however, its association with Wnt/β-catenin signaling was not studied. Two other studies 
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observed that the up-regulation of GLI1 expression in colorectal carcinomas was not always 
consistent with the expression pattern of Shh, suggesting that the Hh pathway might be activated by 
other regulatory mechanisms in colorectal carcinomas (35, 36). Another study reported that Indian 
hedgehog (Ihh) signaling stimulates colonic epithelial differentiation and inhibits proliferation by 
antagonizing Wnt signaling (6), however Yauch et al. have recently demonstrated that Hh ligands 
failed to activate canonical Hh signaling in tumor epithelial cells (19), suggesting that the observed 
up-regulation of GLI1 in colorectal cancer cells may not be a result of activation of upstream Hh 
signaling. A body of evidence points to a regulatory role of Wnt and Hh pathways in stem cells 
development in epithelia, including those of intestine (reviewed in (37)). Additionally, recent 
studies suggest that colorectal tumors might arise from intestinal stem cells (41). Taken together, it 
is likely that cross-talk between the Wnt and Hh pathways exists in the development of colorectal 
cancers and one proposed mechanism of this interaction involves control of GLI1 expression by 
both pathways.  
 
Wnt and Hh are pivotal pathways similar to each other in several respects (42, 43). These pathways 
interact at multiple levels in embryonic organ patterning as well as in the development of some 
cancers. It is likely that different mechanisms are employed for this cross-talk in different contexts. 
In this study, we identify a novel mechanism by which Wnt signaling regulates Hh signaling, and 
demonstrate that this mechanism employs GLI1 mRNA stabilization. To the best of our knowledge, 
this is the first study that demonstrates post-transcriptional regulation of the Hh signaling by the 
Wnt/β-catenin signaling pathway. It is also the first study to identify CRD-BP as a mechanistic link 
between the two pathways. Altogether, this work sheds light on the regulatory role of Wnt signaling 
in controlling Hh signaling, and offers significant new insight in the involvement of the two 
pathways in colorectal cancer development. These findings suggest CRD-BP as a valuable 
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candidate drug target for therapy in cancers associated with deregulation of Wnt/β-catenin and Hh 
signaling pathways.  
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Figure 1: Wnt/β-catenin signaling induces the expression of GLI1. 
a. Northern blot (upper panel) analysis of GLI1 mRNA levels in HeLa cells either untreated or 
treated with the recombinant mouse Wnt-3A (100 ng/ml) for 15 hrs. Immunoblot (lower panel) 
analysis of CRD-BP expression levels in the corresponding cells. 
b. Northern blot (upper panel) analysis of GLI1 mRNA levels in 293T cells transfected with 
pcDNA3.1 or β-catenin/Tcf4. Immunoblot (lower panel) analyses of GLI1 and CRD-BP expression 
levels in the corresponding cells.  
c. Northern blot (upper panel) analysis of GLI1 mRNA levels in DLD1D7Δ15 and LS174 T-L8 
cells untreated or treated with doxycycline (1 μg/ ml) for 24 hrs. Immunoblot (lower panel) analyses 
of GLI1 and CRD-BP expression levels in the corresponding cells. 
7S was used as internal control for northern blot analyses and β-actin as internal control for 
immunoblot analyses. 
Numbers in the figures a. b. and c. represent relative densitometry measurements. 
d. Levels of gli1 mRNA were determined by quantitative RT-PCR in zebrafish transgenic 
Tg(HS:dTCF-GFP) embryos bearing heat shock-inducible dnTCF fused to GFP. GFP-positive 
embryos (dTCF), which expressed dnTCF, were selected by fluorescence and analyzed separately 







Figure 2: Wnt/β-catenin signaling modulates Hh signaling by up-regulating CRD-BP which 
stabilizes GLI1 mRNA. 
a. 293T cells were co-transfected with Tet-off, pTRE-Tight-GLI1 and either pcDNA3.1, β-
catenin/Tcf4, or Flag-CRD-BP. 48 hrs after transfection, transcription was stopped by treatment 
with doxycycline (1 μg/ ml) for the indicated durations, and stability of the GLI1 mRNA was 
analyzed by Northern blotting (upper panels) and presented graphically (lower panel). 
b. Expression levels of GLI1 mRNA determined by northern blot (upper panel) analysis in 293T 
cells transfected with pcDNA3.1 or Flag-CRD-BP. Protein expression of GLI1 and CRD-BP were 
determined by immunoblot (lower panel) analyses in the corresponding cells.  
c. Flag-immunoprecipitation (IP) of UV-crosslinked complexes of the 41-990, 973-1824, 1808-
2730 and 2713-3600 bp fragments of GLI1 mRNA as well as the full length and proteins from 293T 
cells transfected with Flag-CRD-BP or pcDNA3.1 plasmid. The diagram illustrates the position of 
each fragment on GLI1 mRNA. 
d. Northern blot (upper panel) analysis of GLI1 expression in 293T cells and immunoblot (lower 
panels) analyses of GLI1 and CRD-BP expression in 293T and NIH3T3 cells co-transfected with 
pcDNA3.1 and irrelevant shRNA, β-catenin/Tcf4 and irrelevant shRNA or β-catenin/Tcf4 and 
CRD-BP shRNA.  
7S was used as internal control for northern blot analyses and β-actin as internal control for 









Figure 3: Wnt/β-catenin signaling induces the expression of GLI1 in a CRD-BP dependent 
manner. 
a. NIH 3T3 cells were grown in 6 well plates and co-transfected with 8X3’GLI BS-LucII reporter 
plasmid, pSV-40 -galactosidase and irrelevant shRNA or CRD-BP shRNA plasmid then treated 
with Wnt-3A (100 ng/ml) for 15 hrs as indicated. 48 hrs after transfection, the luciferase activity 
was estimated using luciferase reporter assay reagent (Promega). β-galactosidase was used for 
normalization and estimated using β-galactosidase assay reagent (Pierce). 
b. DLD1D7Δ15 cells were grown in 6 well plate and co-transfected with 8X3’GLI BS-LucII 
reporter plasmid, pSV-40 β-galactosidase and Flag-CRD-BP or empty plasmid then treated with 
doxycycline (1 μg/ ml) for 24 hrs, Cyclopamine ( 10 µM) for 24 hours or SAG ( 3nM) for 30 hrs as 
indicated. The luciferase activity was estimated as in 3-a. 
c. 293T cells grown in 6 well plate were co-transfected with 8X3’GLI BS-LucII reporter plasmid, 
pSV-40 β-galactosidase and Flag-CRD-BP or empty plasmid and irrelevant shRNA or GLI1 
shRNA (shGLI1-C). The luciferase activity was estimated as in 3-a. 








Figure 4: GLI1 contributes to β-catenin and CRD-BP-dependent proliferation of colorectal 
cancer cells. 
a. DLD1D7Δ15 and LS174 T-L8 cells were grown in 100 mm dish and co-tansfected with pTK-
puro plasmid and either the empty vector or pcDNA3.1-GLI1 as indicated. 48 hrs after transfection, 
cells from each plate were seeded in five 100 mm plates and the cells were treated with doxicycline 
(1µg/ml) for 72 hrs and puromycin (8 µg /ml) for 10 days. The colonies formed were counted under 
the microscope.  
b. DLD1D7Δ15 and LS174 T-L8 cells grown in 100 mm plates were co-transfected with pTK-puro 
plasmid and irrelevant shRNA, CRD-BP shRNA, irrelevant shRNA and pcDNA3.1-GLI1, or CRD-
BP shRNA and pcDNA3.1-GLI1 as indicated. 48 hrs after transfection, cells from each plate were 
seeded in five 100 mm plates and treated with puromycin (8µg/ml) for 10 days. The colonies were 
counted under the light microscope. 
c. Levels of GLI1 mRNA in primary colorectal normal and tumor human tissue samples determined 
by quantitative RT-PCR.  
d. Immunoblot analysis of proteins isolated from normal (N) and tumor (T) samples of Apc Min -/+ 




SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1 
a. -Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in HeLa cells, either untreated or 
treated with the recombinant mouse Wnt-3A (100 ng/ml) for 15 hrs.. 
b. Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in 293T cells transfected with 
pcDNA3.1 or β-catenin/Tcf4.  
c. Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in DLD1D7Δ15 and LS174 T-L8 
cells untreated or treated with doxycycline (1 μg/ ml) for 24 hrs. 
d. Quantitative real time RT-PCR analysis of GLI1 in DLD1 and HCT116 cells untreated or treated 
with doxycycline (1 μg/ ml) for 24 hrs. 
 
Supplemental Figure 2 
a. -Quantitative real time RT-PCR analysis of GLI1 in 293T cells transfected with pcDNA3.1, β-
catenin/Tcf4 or Flag-CRD-BP as indicated and treated with actinomycin D (10µg/ml) for 4 hours. 
b. -Quantitative real time RT-PCR analysis of Axin2 in 293T cells transfected as indicated in 
Supplemental Figure 2 a and treated with actinomycin D (10µg/ml) for 4 hours. 
c. -Quantitative real time PCR for GLI2 and GLI3 in 293T cells transfected with pcDNA3.1, β-








Supplemental Figure 3 
Quantitative real time RT-PCR (upper panel) and immunoblot (lower panel) analyses of 293T cells 
transfected as indicated. Note that CRD-BP shRNA-3 is only human specific, therefore mCRD-BP 
(mouse CRD-BP) is resistant to down-regulation by shRNA-3.  
*- reported previously in (16) 
 
 
Supplemental Figure 4 
a. Quantitative real time RT-PCR analysis of c-myc and Cyclin D1 in DLD1D7Δ15 and LS174 T-
L8 cells co-tansfected with pTK-puro plasmid and either the empty vector or pcDNA3.1-GLI1 as 
indicated. 48 hrs after transfection, the cells were treated with puromycin (8 µg /ml) for 5 days and 
then with doxicycline (1µg/ml) for 48 hrs. 
b. Quantitative real time RT-PCR analysis of CRD-BP, c-myc and Cyclin D1 in DLD1D7Δ15 and 
LS174 T-L8 cells co-transfected with pTK-puro plasmid and irrelevant shRNA, CRD-BP shRNA, 
irrelevant shRNA and pcDNA3.1-GLI1, or CRD-BP shRNA and pcDNA3.1-GLI1 as indicated. 48 








Supplemental Figure 5 
a. SW620, SW480, and HCT116 cells were grown in 100 mm plates and co-transfected with pTK-
puro plasmid and irrelevant shRNA or GLI1 shRNAs (GLI1-A, GLI1-C). Cells from each plate 
were seeded in five 100 mm plates and treated with puromycin (7 µg) for 10 days. Colonies were 
counted under the microscope. 
b.Quantitative real time RT-PCR for GLI1 of the cells transfected as in Supplemental Figure 5a. 
c. Quantitative real time RT-PCR for GLI1 (upper panel) and immunoblot (lower panels) analyses 
for CRD-BP and β-catenin expression levels of colorectal cancer cell lines. β-actin was used as 
internal control for immunoblot analyses. 
 
Supplemental Figure 6 
Quantitative real time RT-PCR analysis for Gli1 and CRD-BP in colorectal normal and tumor 
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Supplemental Figure 1 
a. -Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in HeLa cells, either 
untreated or treated with the recombinant mouse Wnt-3A (100 ng/ml) for 15 hrs.. 
b. Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in 293T cells transfected 
with pcDNA3.1 or β-catenin/Tcf4.  
c. Quantitative real time RT-PCR analysis of Tcf1 and Axin2 in DLD1D7Δ15 and LS174 
T-L8 cells untreated or treated with doxycycline (1 μg/ ml) for 24 hrs. 
d. Quantitative real time RT-PCR analysis of GLI1 in DLD1 and HCT116 cells untreated 
or treated with doxycycline (1 μg/ ml) for 24 hrs. 
 
Supplemental Figure 2 
a. -Quantitative real time RT-PCR analysis of GLI1 in 293T cells transfected with 
pcDNA3.1, β-catenin/Tcf4 or Flag-CRD-BP as indicated and treated with actinomycin D 
(10µg/ml) for 4 hours. 
b. -Quantitative real time RT-PCR analysis of Axin2 in 293T cells transfected as 
indicated in Supplemental Figure 2 a and treated with actinomycin D (10µg/ml) for 4 
hours. 
c. -Quantitative real time PCR for GLI2 and GLI3 in 293T cells transfected with 






Supplemental Figure 3 
Quantitative real time RT-PCR (upper panel) and immunoblot (lower panel) analyses of 
293T cells transfected as indicated. Note that CRD-BP shRNA-3 is only human specific, 
therefore mCRD-BP (mouse CRD-BP) is resistant to down-regulation by shRNA-3.  
*- reported previously in (16) 
 
 
Supplemental Figure 4 
a. Quantitative real time RT-PCR analysis of c-myc and Cyclin D1 in DLD1D7Δ15 and 
LS174 T-L8 cells co-tansfected with pTK-puro plasmid and either the empty vector or 
pcDNA3.1-GLI1 as indicated. 48 hrs after transfection, the cells were treated with 
puromycin (8 µg /ml) for 5 days and then with doxicycline (1µg/ml) for 48 hrs. 
b. Quantitative real time RT-PCR analysis of CRD-BP, c-myc and Cyclin D1 in 
DLD1D7Δ15 and LS174 T-L8 cells co-transfected with pTK-puro plasmid and irrelevant 
shRNA, CRD-BP shRNA, irrelevant shRNA and pcDNA3.1-GLI1, or CRD-BP shRNA 
and pcDNA3.1-GLI1 as indicated. 48 hrs after transfection, the cells were treated with 






Supplemental Figure 5 
a. SW620, SW480, and HCT116 cells were grown in 100 mm plates and co-transfected 
with pTK-puro plasmid and irrelevant shRNA or GLI1 shRNAs (GLI1-A, GLI1-C). Cells 
from each plate were seeded in five 100 mm plates and treated with puromycin (7 µg) for 
10 days. Colonies were counted under the microscope. 
b.Quantitative real time RT-PCR for GLI1 of the cells transfected as in Supplemental 
Figure 5a. 
c. Quantitative real time RT-PCR for GLI1 (upper panel) and immunoblot (lower panels) 
analyses for CRD-BP and β-catenin expression levels of colorectal cancer cell lines. β-
actin was used as internal control for immunoblot analyses. 
 
Supplemental Figure 6 
Quantitative real time RT-PCR analysis for Gli1 and CRD-BP in colorectal normal and 
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Supplemental Table 1: Sequences of primers used for PCR amplification of GLI1 cDNA fragments 
Primers Forward Reverse 
fragment 1 5’ATTTAGGTGACACTATAGAACCCAGACAGAGTGTCCCC 3’ 5’ CGTGCACTTGTGTGGCTT 3’ 
fragment 2 5’ATTTAGGTGACACTATAGAATCCCTGCCTGGCCTTATG 3’ 5’ATCAAAGTCCAGGCAAGGC 3’ 
fragment 3 5’ATTTAGGTGACACTATAGAA TCCCTGCCTGGCCTTATG 3’ 5’ATCAAAGTCCAGGCAAGGC 3’ 
fragment 4 5’ATTTAGGTGACACTATAGAACCTTGCCTGGACTTTGATTC3’ 5’CTGATGCAGTTCCTTTATTATCAGG3’ 
The underlined sequences represent SP6 promoter sequences. 
 
 Supplemental Table 2: Sequences of primers used for quantitative real-time RT-PCR 
 Primers   Forward Reverse 
gli1 (Zebrafish) 5’CAAGGTGGCACAAGAAGACA3’ 5’TAGGTGGTCGAGGCGAATAC3’ 
GLI1 (human)  5’GTGCAAGTCAAGCCAGAACA3’ 5’ATAGGGGCCTGACTGGAGAT3’ 
Gli1 (mouse) 5’ATGAAGCTAGGGGTCCAGGT3’ 5’AGAAGGGAACTCACCCCAGT3’ 
GLI2 5’CTACAGTCCGCAAGGCCTAC3’ 5’TCAGGTGCCACTTCTGTCTG3’ 
GLI3 5’GAGCACTTGATGCTCCACAA3’ 5’GGGTGCTCTTCAGCTTTGAG3’ 
Cyclin D1 5’CCGTCCATGCGGAAGATC3’ 5’GAAGACCTCCTCCTCGCACT3’ 
c-myc 5’TACCCTCTCAACGACAGCAG3’ 5’TCTTGACATTCTCCTCGGTG3’ 
Tcf1 (TCF7)  5’TGCAGCTATACCCAGGCTGG3’ 5’CCTCGACCGCCTCTTCTTC3’ 
Axin2 5’TCACCAAACCCATGTCTGTC3’ 5’TCCAGGAAAGTTCGGAACAG3’ 
CRD-BP (human) 5’CTGAAGATCCTGGCCCATAA3’ 5’AAGGTCTTGCAACGAGGAGA3’
CRD-BP(mouse) 5’GGCTGCTCCCTATAGCTCCT3’ 5’CTGGTGGTGCAATCTTGATG3’ 
GAPDH (human) 5’ATGGTTGCCACTGGGGATCT3’ 5’TGCCAAAGCCTAGGGGAAGA3’
GAPDH (mouse) 5’AATGTGTCCGTCGTGGATCT3’ 5’CCCTGTTGCTGTAGCCGTAT3’ 
 
